Table 1.
HPV16 E7 variants tested and associated nuclear protein levels of E7.
| Variants | Original Codon | Mutant Codon | Nucleotide Change | Control (No.) | Precancer (No.) | E7 * |
|---|---|---|---|---|---|---|
| Wild type | 1 | |||||
| Control | ||||||
| H9R | CAT | CGT | A > G | 1 | 0 | 0.8 |
| D14E | GAT | GAA | T > A | 0 | 1 (CIN2 **) | 0.11 |
| D21N | GAT | AAT | G > A | 1 | 0 | 0.92 |
| N29H | AAT | CAT | A > C | 0 | 1 (CIN2 **) | 0.3 |
| N29S | AAT | AGT | A > G | 2 | 0 | 0.018 |
| E33K | GAG | AAG | G > A | 2 | 0 | 0.2 |
| T56I | ACC | ATC | C > T | 1 | 0 | 0.55 |
| D62N | GAC | AAC | G > A | 1 | 0 | 0.11 |
| S63F | TCT | TTT | C > T | 1 | 0 | 0.1 |
| S63P | TCT | CCT | T > C | 1 | 0 | 0.3 |
| T64M | ACG | ATG | C > T | 1 | 0 | 0.11 |
| E80K | GAA | AAA | G > A | 1 | 0 | 0.26 |
| D81N | GAC | AAC | G > A | 1 | 0 | 0.42 |
| P92L | CCC | CTC | C > T | 2 | 0 | 0.1 |
| P92S | CCC | TCC | C > T | 2 | 0 | 0.68 |
| Precancer | ||||||
| P6L | CCT | CTT | C > T | 1 | 1 (CIN3 **) | 1.1 |
| H51N | CAT | AAT | C > A | 6 | 3 (CIN3/AIS ***) | 0.46 |
| R77S | CGT | AGT | C > A | 1 | 1 (AIS) | 0.99 |
*: p < 0.05 (E7 control ratio vs. E7 precancer ratio). (Ratio from E7 variants/E7 wild types in the control and precancer groups, respectively). **: Cervical intraepithelial neoplasia (CIN)\2 or 3; ***: AIS, Adenocarcinoma in situ. Columns 2–4 information from reference [20].